Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWY0V1)

• Drug Name: LIPO-5 Drug Info
• Synonyms: HIV vaccine (lipoprotein), ANRS/Aventis Pasteur

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMWY0V1

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Negative factor (HIV nef)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
F4co vaccine	DM6UQNW	Human immunodeficiency virus infection	1C62	Phase 2	[3]
Ad35-GRIN	DM4L28K	Human immunodeficiency virus infection	1C62	Phase 1/2	[4]
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[4]
GSK-732461	DMJ0ZB6	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[5]
MYRISTIC ACID	DMYX0BL	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Human immunodeficiency virus GAG protein (HIV gag)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bevirimat	DML2D8Q	Human immunodeficiency virus infection	1C62	Phase 2	[7]
Ad35-GRIN	DM4L28K	Human immunodeficiency virus infection	1C62	Phase 1/2	[4]
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[4]
TBC-M4	DM9CDPO	Human immunodeficiency virus infection	1C62	Phase 1	[8]
RVSVIN HIV-1 gag vaccine	DMYRPC8	Human immunodeficiency virus infection	1C62	Phase 1	[9]
GSK-732461	DMJ0ZB6	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[5]
PA-1050040	DMF4KPM	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[10]
Gem 92	DM4ZDVY	Human immunodeficiency virus-1 infection	1C62	Discontinued in Phase 1	[11]
MPC-9055	DMCMNKV	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[12]
MPI-461359	DMAVD4Q	Human immunodeficiency virus infection	1C62	Terminated	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus GAG protein (HIV gag)	TTFGZB6	GAG_HV1H2	Not Available	[2]
Human immunodeficiency virus Negative factor (HIV nef)	TT4NXYM	NEF_HV1A2	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT01492985) Lipopeptide Immunisation With GTU-multiHIV Trial. U.S. National Institutes of Health.
• [2] HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
• [3] EP patent application no. 2621528, Vaccine.
• [4] A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
• [5] Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013.
• [6] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [7] Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65.
• [8] A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
• [9] Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81.
• [10] US patent application no. 2015,0105,350, Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections.
• [11] Technology evaluation: GEM-92, Hybridon Inc. Curr Opin Mol Ther. 1999 Aug;1(4):521-3.
• [12] New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation . Antimicrob Agents Chemother. 2009 December; 53(12): 5080-5087.
• [13] Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012 Aug 6;9:63.